Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2010

View Archived Issues

Scientists design PIE-12-trimer that specifically inhibits HIV entry into host cells

Phase I data presented on hypnotic agent GF-015535-00

Interim phase I/II data suggest safety of everolimus in advanced HCC

Novartis reports on clinical development of LDE-225

BI-10773 improves glycemic control in large study in type 2 diabetes

Phico Therapeutics details phase I tolerability of PT1.2

Immatics raises funds to advance cancer vaccine portfolio

NasVax begins phase IIa trial of oral anti-CD3 immunotherapy

University of Kansas claims new HSP 90 inhibitors

Pro-Pharmaceuticals and Numoda collaborate on phase III Davanat trial

FDA and EMA to review vandetanib for advanced medullary thyroid cancer

AnGes receives fast track status for Collategene in critical limb ischemia

Santaris Pharma to initiate phase IIa trial of miravirsen in hepatitis C

Dynavax begins phase Ib study of its universal flu vaccine candidate

GSK to use biomarker from OncoMethylome in immunotherapy program

S*BIO obtains funding to support clinical programs

DiagnoCure files PMA application with FDA for Progensa PCA3 assay

RXi and EyeGate Pharma collaborate on ocular drug delivery system

Abbott and Reata to codevelop bardoxolone methyl for CKD

New dual GLP-1/glucagon receptor agonists described

FDA orphan drug status for darinaparsin in peripheral T-cell lymphoma

Vifor and Kissei Pharma partner to develop and market PA-21 in Japan

European orphan status granted to rFVIIIFc in hemophilia A

OP Bio Factory and Nagoya University disclose new beta-NGF enhancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...